EGFR
Universal Cellular Machinery · Phosphorylation & Kinase Signaling Cascades
How does an epidermal growth signal reach the inside of a cell?
EGFR makes a receptor that binds growth-related signals outside the cell. Activation relays messages that influence cellular behavior, while drug relevance depends on a particular tumor's findings.
- Common Gene Name
- epidermal growth factor receptor
- NCBI Gene ID
- 1956
- Chromosome
- 7
Clinical Evidence Status
Established disease relationshipTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (27 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| non-small cell lung carcinoma | ClinGen gene-disease validity | Definitive | Autosomal dominant | View source 2020-07-30 |
| Lung cancer | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2017-12 | |
| Cholangiocarcinoma | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2017-12 | |
| Afatinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Amivantamab-vmjw | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Atezolizumab (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Cemiplimab-rwlc (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Cetuximab (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Dacomitinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Durvalumab (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Erlotinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Gefitinib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Ipilimumab (5) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Mobocertinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Nivolumab (4) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Osimertinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Panitumumab (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Pembrolizumab (4) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Pemetrexed (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Ramucirumab (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Tepotinib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Tremelimumab-actl (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Datopotamab Deruxtecan-dlnk (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Lazertinib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Sevabertinib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Sunvozertinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Telisotuzumab Vedotin-tllv (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Universal Cellular Machinery